GAITHERSBURG, Md., May 8 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that Chief Executive Officer Stanley C. Erck will participate in two upcoming investor conferences: the UBS Global Generic & Specialty Pharmaceuticals Conference at the Grand Hyatt in New York and the Rodman & Renshaw 4th Annual Global Healthcare Conference, held at Le Meridien Beach Plaza Hotel at the Sea Club in Monte Carlo, Monaco.
Mr. Erck will review Iomai’s progress in its four clinical-stage patch- based vaccines and immunostimulants for use in influenza, pandemic influenza and travelers’ diarrhea. The presentation at the UBS conference will take place tomorrow, May 9 at 3 p.m., Eastern Time. At the Rodman & Renshaw event, Mr. Erck will speak at May 14 at 12:35 p.m., Monaco Time, with a breakout immediately following.
To access the live audio webcast or the subsequent archived recording, log on to the Investor Relations section on the Overview page of the Iomai website at www.iomai.com . Please connect to Iomai’s website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.
About Iomai Corporation
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers’ diarrhea. For more information on Iomai, please visit www.iomai.com .
Iomai Corporation
CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel of Iomai Corporation, +1-301-556-4478,investors@iomai.com; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, breid@weisscommpartners.com, for Iomai Corp.
Web site: http://www.iomai.com//
